Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in North Carolina: - Duke Cancer Center Cary — Cary, North Carolina
- Duke Cancer Center - Investigational Chemotherapy Service — Durham, North Carolina
- Duke Cancer Center — Durham, North Carolina
- Duke University Hospital - Vascular Interventional Radiology — Durham, North Carolina
- Duke Cancer Center Raleigh — Raleigh, North Carolina
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in North Carolina: - Duke University Hospital — Durham, North Carolina
- Duke University Medical Center, Duke Cancer Center — Durham, North Carolina
- Duke University Medical Center — Durham, North Carolina
- FirstHealth Cancer Center — Pinehurst, North Carolina
- FirstHealth Moore Regional Hospital — Pinehurst, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in North Carolina: - Messino Cancer Center — Asheville, North Carolina
- The University of North Carolina At Chapel Hill — Chapel Hill, North Carolina
- Oncology Specialists of Charlotte — Charlotte, North Carolina
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
- Duke Cancer Center Raleigh — Raleigh, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…
Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in North Carolina: - GSK Investigational Site — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uv…
Sponsor: IDEAYA Biosciences
NCT ID: NCT03947385
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting Network
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after the…
Sponsor: NSABP Foundation Inc
NCT ID: NCT07058012
Sites in North Carolina: - First Health of the Carolinas — Pinehurst, North Carolina
Phase 2 Recruiting Industry
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable …
Sponsor: Kahr Bio Australia Pty Ltd
NCT ID: NCT07235293
Sites in North Carolina: - Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Industry
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling…
Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT ID: NCT06751329
Sites in North Carolina: - Carolina BioOncology Institute, LLC — Huntersville, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will…
Sponsor: Arvinas Inc.
NCT ID: NCT07749586
Sites in North Carolina: - Clinical Trial Site — Huntersville, North Carolina
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in North Carolina: - Exelixis Clinical Site #12 — Durham, North Carolina
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1 Recruiting Industry
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…
Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and …
Sponsor: Xencor, Inc.
NCT ID: NCT05433142
Sites in North Carolina: - Xencor Investigative Site — Charlotte, North Carolina
- Xencor Investigative Site — Durham, North Carolina
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1 Recruiting Industry
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06040541
Sites in North Carolina: - Duke Cancer Center — Durham, North Carolina
- Carolina BioOncology Institute — Huntersville, North Carolina
Phase 1 Recruiting Industry
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…
Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Sponsor: Alterome Therapeutics, Inc.
NCT ID: NCT06835569
Sites in North Carolina: - Research Site — Durham, North Carolina
Phase 1 Recruiting Industry
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study …
Sponsor: Pliant Therapeutics, Inc.
NCT ID: NCT06270706
Sites in North Carolina: - Carolina Cancer Research Center — Wilson, North Carolina
Phase 1 Recruiting Industry
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Sponsor: Pheon Therapeutics
NCT ID: NCT07127874
Sites in North Carolina: - PHN-012-001 Site — Durham, North Carolina
Phase 1 Recruiting Industry
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered o…
Sponsor: MOMA Therapeutics
NCT ID: NCT06974110
Sites in North Carolina: - Investigative Site #131 — Raleigh, North Carolina